224 related articles for article (PubMed ID: 32913191)
1. CYP2S1 is a synthetic lethal target in BRAF
Li Y; Su X; Feng C; Liu S; Guan H; Sun Y; He N; Ji M; Hou P
Signal Transduct Target Ther; 2020 Sep; 5(1):191. PubMed ID: 32913191
[TBL] [Abstract][Full Text] [Related]
2. Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF
Zhang P; Guan L; Sun W; Zhang Y; Du Y; Yuan S; Cao X; Yu Z; Jia Q; Zheng X; Meng Z; Li X; Zhao L
Clin Transl Med; 2024 May; 14(5):e1694. PubMed ID: 38797942
[TBL] [Abstract][Full Text] [Related]
3. Heterogenous nature of gene expression patterns in BRAF-like papillary thyroid carcinomas with BRAF
Nagayama Y; Mishima H
Endocrine; 2019 Dec; 66(3):607-613. PubMed ID: 31478162
[TBL] [Abstract][Full Text] [Related]
4. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial metabolism is inhibited by the HIF1α-MYC-PGC-1β axis in BRAF V600E thyroid cancer.
Gao Y; Yang F; Yang XA; Zhang L; Yu H; Cheng X; Xu S; Pan J; Wang K; Li P
FEBS J; 2019 Apr; 286(7):1420-1436. PubMed ID: 30768848
[TBL] [Abstract][Full Text] [Related]
6. β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAF
Zou M; BinEssa HA; Al-Malki YH; Al-Yahya S; Al-Alwan M; Al-Jammaz I; Khabar KSA; Almohanna F; Assiri AM; Meyer BF; Alzahrani AS; Al-Mohanna FA; Shi Y
Mol Cancer Ther; 2021 Sep; 20(9):1603-1613. PubMed ID: 34224366
[No Abstract] [Full Text] [Related]
7. Oncogenic Properties of the Antisense lncRNA
Esposito R; Esposito D; Pallante P; Fusco A; Ciccodicola A; Costa V
Cancer Res; 2019 May; 79(9):2124-2135. PubMed ID: 30862713
[No Abstract] [Full Text] [Related]
8. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
[TBL] [Abstract][Full Text] [Related]
9. Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma.
Lee SJ; Lee MH; Kim DW; Lee S; Huang S; Ryu MJ; Kim YK; Kim SJ; Kim SJ; Hwang JH; Oh S; Cho H; Kim JM; Lim DS; Jo YS; Shong M
PLoS One; 2011 Jan; 6(1):e16180. PubMed ID: 21249150
[TBL] [Abstract][Full Text] [Related]
10. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
[TBL] [Abstract][Full Text] [Related]
11. AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma.
Sisdelli L; Cordioli MICV; Vaisman F; Moraes L; Colozza-Gama GA; Alves PAG; Araújo ML; Alves MTS; Monte O; Longui CA; Cury AN; Carvalheira G; Cerutti JM
Pediatr Blood Cancer; 2019 Jul; 66(7):e27707. PubMed ID: 30924609
[TBL] [Abstract][Full Text] [Related]
12. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
13. Low-Density Lipoprotein Receptor Is a Key Driver of Aggressiveness in Thyroid Tumor Cells.
Revilla G; Ruiz-Auladell L; Vallverdú NF; Santamaría P; Moral A; Pérez JI; Li C; Fuste V; Lerma E; Corcoy R; Pitoia F; Escolà-Gil JC; Mato E
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446330
[TBL] [Abstract][Full Text] [Related]
14. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF
Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y
J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001
[TBL] [Abstract][Full Text] [Related]
16. BRAF
Traversi F; Stooss A; Dettmer MS; Charles RP
Thyroid; 2021 May; 31(5):787-799. PubMed ID: 33012268
[No Abstract] [Full Text] [Related]
17. Evaluation of the expression levels of BRAF
Tran TV; Dang KX; Pham QH; Nguyen UD; Trinh NTT; Hoang LV; Ho SA; Nguyen BV; Nguyen DT; Trinh DT; Tran DN; Orpana A; Stenman UH; Stenman J; Ho TH
BMC Cancer; 2020 May; 20(1):368. PubMed ID: 32357861
[TBL] [Abstract][Full Text] [Related]
18. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.
de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046
[TBL] [Abstract][Full Text] [Related]
19. Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.
Boufraqech M; Patel D; Nilubol N; Powers A; King T; Shell J; Lack J; Zhang L; Gara SK; Gunda V; Klubo-Gwiezdzinska J; Kumar S; Fagin J; Knauf J; Parangi S; Venzon D; Quezado M; Kebebew E
Thyroid; 2019 Jan; 29(1):79-92. PubMed ID: 30398411
[TBL] [Abstract][Full Text] [Related]
20. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.
Durante C; Tallini G; Puxeddu E; Sponziello M; Moretti S; Ligorio C; Cavaliere A; Rhoden KJ; Verrienti A; Maranghi M; Giacomelli L; Russo D; Filetti S
Eur J Endocrinol; 2011 Sep; 165(3):455-63. PubMed ID: 21653734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
